Literature DB >> 5765021

Interaction of the anticoagulant drug warfarin and its metabolites with human plasma albumin.

R A O'Reilly.   

Abstract

The interaction of the anticoagulant drug warfarin and its metabolites with human plasma albumin was studied by equilibrium dialysis. A 20-fold variation of buffer ionic strength (0.017-0.340) caused no significant change in the warfarin association constant. But the binding strength rose significantly as the pH was increased from 6.0 to 9.0 and then declined at pH 10.0. The 6-, 7-, and 8-hydroxywarfarin metabolites showed a 7- to 23-fold reduction in binding strength at pH 10.0. These data indicate that the molecular basis of the interaction is nonelectrostatic and that the introduction of polar hydroxyl groups on the coumarin nucleus by metabolism reduces its hydrophobic binding surface. The interaction was markedly exothermic and showed a positive entropy (increased molecular disorder), which suggests cooperative hydrogen and hydrophobic bonding as the molecular basis for the binding of warfarin to albumin. The marked albumin binding and nonpolar character of warfarin explains the respective absence and presence of the unchanged drug in urine and plasma of warfarintreated patients, while the more polar character and lesser albumin binding of the metabolites probably determines their absence in plasma and presence in urine. The relatively marked binding to albumin of the 4'-hydroxywarfarin metabolite suggests that it may occur in the plasma of warfarin-treated patients. The data suggest that a direct correlation exists between the interaction of warfarin with plasma albumin and the interaction with the warfarin receptor site.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5765021      PMCID: PMC322205          DOI: 10.1172/JCI105968

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

1.  The binding of salicylic acid and related substances to purified proteins.

Authors:  C DAVISON; P K SMITH
Journal:  J Pharmacol Exp Ther       Date:  1961-08       Impact factor: 4.030

2.  Testosterone binding to bovine and human serum albumin: the role of tyrosine groups.

Authors:  E K OYAKAWA; B H LEVEDAHL
Journal:  Arch Biochem Biophys       Date:  1958-03       Impact factor: 4.013

3.  Thermodynamics of chelation by tetracyclines.

Authors:  L Z Benet; J E Goyan
Journal:  J Pharm Sci       Date:  1966-11       Impact factor: 3.534

4.  The binding of penicillins to bovine serum albumin.

Authors:  P M Keen
Journal:  Biochem Pharmacol       Date:  1966-04       Impact factor: 5.858

Review 5.  The pharmacological basis of oral anticoagulant therapy.

Authors:  P M Aggeler; R A O'Reilly
Journal:  Thromb Diath Haemorrh Suppl       Date:  1966

6.  Determination of plasma-thiocyanate binding and the Donnan ratio under simulated physiological conditions.

Authors:  M Pollay; A Stevens; C Davis
Journal:  Anal Biochem       Date:  1966-11       Impact factor: 3.365

7.  Potentiation of anticoagulant effect of warfarin by phenylbutazone.

Authors:  P M Aggeler; R A O'Reilly; L Leong; P E Kowitz
Journal:  N Engl J Med       Date:  1967-03-02       Impact factor: 91.245

8.  Rapid fluorometric assay for plasma warfarin.

Authors:  M Corn; R Berberich
Journal:  Clin Chem       Date:  1967-02       Impact factor: 8.327

9.  Studies on the coumarin anticoagulant drugs: interaction of human plasma albumin and warfarin sodium.

Authors:  R A O'Reilly
Journal:  J Clin Invest       Date:  1967-05       Impact factor: 14.808

10.  Metabolic clearance rates of pregnenolone, 17-acetoxypregnenolone and their sulphate esters in man and in rabbit.

Authors:  D Y Wang; R D Bulbrook; F Ellis; M M Coombs
Journal:  J Endocrinol       Date:  1967-11       Impact factor: 4.286

View more
  12 in total

1.  Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.

Authors:  Drew R Jones; So-Young Kim; Michael Guderyon; Chul-Ho Yun; Jeffery H Moran; Grover P Miller
Journal:  Chem Res Toxicol       Date:  2010-05-17       Impact factor: 3.739

2.  Changes in drug metabolism with increasing age: 1. warfarin binding and plasma proteins.

Authors:  M J Hayes; M J Langman; A H Short
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

Review 3.  Interindividual differences in the response to oral anticoagulants.

Authors:  A M Breckenridge
Journal:  Drugs       Date:  1977-11       Impact factor: 9.546

Review 4.  Protein binding of coumarin anticoagulants in disease states.

Authors:  K Bachmann; R Shapiro
Journal:  Clin Pharmacokinet       Date:  1977 Mar-Apr       Impact factor: 6.447

5.  Binding of certain acidic drugs to human albumin: theoretical and practical estimation of fundamental parameters.

Authors:  J P Tillement; R Zini; P d' Athis; G Vassent
Journal:  Eur J Clin Pharmacol       Date:  1974-07-26       Impact factor: 2.953

6.  Could geriatric characteristics explain the under-prescription of anticoagulation therapy for older patients admitted with atrial fibrillation? A retrospective observational study.

Authors:  Sandra De Breucker; Gertraud Herzog; Thierry Pepersack
Journal:  Drugs Aging       Date:  2010-10-01       Impact factor: 3.923

7.  A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites.

Authors:  Jamil A Haque; Matthew G McDonald; John D Kulman; Allan E Rettie
Journal:  Blood       Date:  2013-12-02       Impact factor: 22.113

8.  Displacement of phenprocoumon (Marcumar) from albumin by sulfonylurea compounds, suramin, and ioglycamic acid.

Authors:  B Hüthwohl; E Jähnchen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

9.  Warfarin metabolism in man: identification of metabolites in urine.

Authors:  R J Lewis; W F Trager
Journal:  J Clin Invest       Date:  1970-05       Impact factor: 14.808

10.  Interactions of some phenylindanedione anticoagulants with human serum albumin.

Authors:  J Paubel; P Niviere; M Payard; J C Rabadeux; C P Pinazzi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.